Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
| ▸ | APEX1 | P27695 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
| ▸ | PRKCI | P41743 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | PRNP | P04156 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | RAD52 | P43351 | 1/20 | 0.45 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.43 |
| ▸ | MMP12 | P39900 | 2/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14723315 | 0.83 | MAPT (0.56) | MAPTALDH1A1KDM4ETDP1APEX1 | |
| SCHEMBL13373332 | 0.83 | MAPT (0.48) | MAPTALDH1A1KDM4ETDP1APEX1 | |
| SCHEMBL3044280 | 0.83 | MAPT (0.61) | MAPTALDH1A1KDM4ETDP1APEX1 | |
| SCHEMBL31150482 | 0.83 | MAPT (0.56) | MAPTALDH1A1KDM4ETDP1APEX1 | |
| SCHEMBL3050263 | 0.83 | MAPT (0.48) | MAPTALDH1A1KDM4ETDP1APEX1 | |
| SCHEMBL23124230 | 0.83 | MAPT (0.61) | MAPTALDH1A1KDM4ETDP1APEX1 | |
| SCHEMBL31444162 | 0.83 | MAPT (0.48) | MAPTALDH1A1KDM4ETDP1APEX1 | |
| SCHEMBL31153163 | 0.83 | MAPT (0.61) | MAPTALDH1A1KDM4ETDP1APEX1 | |
| SCHEMBL14511179 | 0.82 | MAPT (0.68) | MAPTALDH1A1KDM4ETDP1APEX1 | |
| SCHEMBL12445185 | 0.79 | MAPT (0.65) | MAPTALDH1A1KDM4ETDP1APEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119287465-A | Wear-resistant duplex stainless steel belt and processing technology thereof | 江苏甬金金属科技有限公司 | 2025-01-10 | — | — | CN | claimed |
| CN-118164917-A | Alpha-fluoroenamine compound and preparation method and application thereof | 南京工业大学 | 2024-06-11 | — | — | CN | claimed |
| CN-119287465-A | Wear-resistant duplex stainless steel belt and processing technology thereof | 江苏甬金金属科技有限公司 | 2025-01-10 | — | — | CN | disclosed |
| CN-118164917-A | Alpha-fluoroenamine compound and preparation method and application thereof | 南京工业大学 | 2024-06-11 | — | — | CN | disclosed |
| CN-115651206-B | Cage-shaped synthetic supermolecular material, preparation method and application thereof | 广州大学 | 2023-11-24 | — | — | CN | disclosed |
| CN-115651206-A | Cage-shaped synthetic supramolecular material, preparation method and application thereof | 广州大学 | 2023-01-31 | — | — | CN | disclosed |
| CN-110191882-B | Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them | 株式会社大熊制药 | 2022-09-13 | — | — | CN | disclosed |
| US-10981917-B2 | Heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2021-04-20 | — | — | US | disclosed |
| WO-2020247160-A1 | CONDENSED TRYCICLIC PYRROLES AS ALPHA-1 ANTITRYPSIN MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-12-10 | — | — | WO | disclosed |
| EP-3159335-B1 | NOVEL HETEROCYCLIC COMPOUND | DAE WOONG PHARMA (KR) | 2020-04-29 | — | — | EP | disclosed |
| US-10081634-B2 | Heterocyclic compound | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2018-09-25 | — | — | US | disclosed |
| EP-2935244-B1 | NOVEL BENZIMIDAZOLE DERIVATIVES AS KINASE INHIBITORS | SELVITA S A (PL) | 2018-06-27 | — | — | EP | disclosed |
| US-20180062213-A1 | Nonaqueous Electrolyte and Nonaqueous Secondary Battery | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2018-03-01 | — | — | US | disclosed |
| EP-3279997-A1 | NONAQUEOUS ELECTROLYTE AND NONAQUEOUS SECONDARY BATTERY | Asahi Kasei Kabushiki Kaisha (JP) | 2018-02-07 | — | — | EP | disclosed |
| EP-3159335-A2 | NOVEL HETEROCYCLIC COMPOUND | Daewoong Pharmaceutical Co., Ltd. (KR) | 2017-04-26 | — | — | EP | disclosed |
| US-20170088551-A1 | NOVEL HETEROCYCLIC COMPOUND | Daewoong Pharmaceutical., Ltd. (KR) | 2017-03-30 | — | — | US | disclosed |
| WO-1999051619-A1 | ARABINOFURANOSYL BENZIMIDAZOLES AS ANTIVIRAL AGENTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1999-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10981917-B2 | Heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | RNASE1, AARS1, DHPS | MAPT 3729/4885ALDH1A1 2364/4885KDM4E 3070/4885 |
| US-10081634-B2 | Heterocyclic compound | AARS1, NSUN3, RNASE1 | MAPT 3681/4885ALDH1A1 1349/4885KDM4E 3488/4885 |
| US-20180062213-A1 | Nonaqueous Electrolyte and Nonaqueous Secondary Battery | BPTF, BRD4, KCNN2 | MAPT 1283/4885ALDH1A1 3497/4885KDM4E 2256/4885 |
| US-20170088551-A1 | NOVEL HETEROCYCLIC COMPOUND | AARS1, TARBP1, NSUN3 | MAPT 3773/4885ALDH1A1 2054/4885KDM4E 3544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.